Prospective randomised placebo-controlled trial comparing glargine + exenatide (n = 137) vs. glargine + placebo (n = 122) Follow up, 30 weeks HbA1c decreased by 1.74% with glargine + exenatide vs. 1.04% with glargine + placebo Weight decreased by 1.8 kg with glargine + exenatide, increased by 1.0 kg with glargine + placebo Insulin increased 13 U/day with glargine + exenatide vs. 20 U/day with glargine + placebo Estimated rate of minor hypoglycaemia was similar between groups. This evidence concerns the gene INS and Hypoglycemia.